Author: "Alkhatib, Nimer" / Publisher: american society of clinical oncology (asco) - Searchworks@Jio Institute Digital Library Search Results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Your search keyword '"Alkhatib, Nimer"' showing total 7 results

Start Over Author "Alkhatib, Nimer" Publisher american society of clinical oncology (asco)

7 results on '"Alkhatib, Nimer"'

1. Economic evaluation of crizotinib, alectinib, ceritinib, and brigatininb in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) as second-line treatment.

Author: Alkhatib, Nimer S., primary, Choi, Briana, additional, Halawah, Hala, additional, Calamia, Matthias, additional, Gulick, Dexter, additional, Manasrah, AlMothana, additional, Alkhdour, Odai, additional, McBride, Ali, additional, and Abraham, Ivo, additional
Published: 2021
Full Text: View/download PDF

2. Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis.

Author: Obeng-Kusi, Mavis, primary, Arku, Daniel, additional, Alrawashdh, Neda, additional, Choi, Briana, additional, Alkhatib, Nimer S., additional, McBride, Ali, additional, and Abraham, Ivo, additional
Published: 2021
Full Text: View/download PDF

3. Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naïve anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).

Author: Choi, Briana, primary, Alkhatib, Nimer S., additional, Halawah, Hala, additional, Calamia, Matthias, additional, Gulick, Dexter, additional, Manasrah, AlMothana, additional, Alkhdour, Odai, additional, McBride, Ali, additional, and Abraham, Ivo, additional
Published: 2021
Full Text: View/download PDF

4. Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC).

Author: Riaz, Irbaz Bin, primary, Almutairi, Abdulaali, additional, Lang, Daenielle K., additional, Asghar, Noureen, additional, Riaz, Anum, additional, Yao, Yuan, additional, Sipra, Qurat Ul Ain Riaz, additional, Ryu, Alexander J., additional, Alkhatib, Nimer S, additional, Oh, Mok, additional, Abraham, Ivo, additional, Murad, M. Hassan, additional, and Kohli, Manish, additional
Published: 2020
Full Text: View/download PDF

5. 30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa).

Author: Alrawashdh, Neda, primary, Oh, Mok, additional, Almutairi, Abdulaali, additional, Alkhatib, Nimer S, additional, Babiker, Hani M., additional, MacDonald, Karen, additional, McBride, Ali, additional, and Abraham, Ivo, additional
Published: 2019
Full Text: View/download PDF

6. Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).

Author: Choi, Briana, primary, Alkhatib, Nimer S, additional, Pae, Elizabeth, additional, Babiker, Hani M., additional, Garland, Linda L., additional, Henglefelt, Alyssa, additional, McBride, Ali, additional, and Abraham, Ivo, additional
Published: 2019
Full Text: View/download PDF

7. Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS).

Author: Alkhatib, Nimer S, primary, Choi, Briana, additional, Pae, Elizabeth, additional, Babiker, Hani M., additional, Garland, Linda L., additional, Henglefelt, Alyssa, additional, McBride, Ali, additional, and Abraham, Ivo, additional
Published: 2019
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results